Tetraphase Pharmaceuticals to Present Eravacycline and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
128
Tetraphase Pharmaceuticals to Present Eravacycline and TP-6076 Data at ASM Microbe 2018

– Four Abstracts Selected for Poster Presentations –

– Presentations Include New Eravacycline Pooled Analysis of IGNITE 1 and IGNITE4 and Data Highlighting the Pre-Clinical Activity of TP-6076 –

WATERTOWN, Mass., May 21, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH ), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced four poster presentations at the American Society for Microbiology (ASM) Microbe 2018 Annual Meeting, taking place June 7-11 in Atlanta, GA. Presentations will include information about the Company’s lead drug candidate, eravacycline, which is currently under review by the United States Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal infections (cIAI), as well as data for TP-6076, its second-generation candidate to target MDR Gram-negative bacteria, which is currently in Phase 1 clinical testing.

The details for the data presentations at ASM are as follows:

Eravacycline poster presentations

Poster title:  Microbiological Efficacy of Eravacycline Against Enterobacteriaceae and Acinetobacter , Including MDR Isolates: A Pooled Analysis from IGNITE1 and IGNITE4, Two Phase 3 Trials of Complicated Intra-Abdominal Infection Date and time: Saturday, June 9 from 11:00 a.m. – 1:00 p.m. ET Location: Exhibit and Poster Hall, Building B, Halls B2-B5 Poster number:   629 Session information: 236 - AAR09 - Pharmacological Studies of Antimicrobial Agents Pre-NDA (Phase 2/3): New Agents Between Phase 2 and FDA Approval

Poster Title:   In Vitro Activity of Eravacycline and Comparators Against Enterobacteriaceae , Acinetobacter baumannii , Stenotrophomonas maltophilia , Including Multidrug-Resistant Isolates, Collected Globally in 2016 Date and time: Saturday, June 9 from 11:00 a.m. – 1:00 p.m. ET Location: Exhibit and Poster Hall, Building B, Halls B2-B5 Poster number: 630 Session information: 236 - AAR09 - Pharmacological Studies of Antimicrobial Agents Pre-NDA (Phase 2/3): New Agents Between Phase 2 and FDA Approval

Poster title:   Eravacycline In Vitro Activity Against Clinical Isolates Obtained in the U.S. in 2016 from Urinary and Gastrointestinal Sources, Including Drug-resistant Pathogens Date and time: Saturday, June 9 from 11:00 a.m. – 1:00 p.m. ET Location: Exhibit and Poster Hall, Building B, Halls B2-B5 Poster number: 631 Session information: 236 - AAR09 - Pharmacological Studies of Antimicrobial Agents Pre-NDA (Phase 2/3): New Agents Between Phase 2 and FDA Approval

TP-6076 poster presentation

Poster title:  TP-6076 is Active Against Bacterial Isolates Carrying Emergent Resistance Types Date and time: Saturday, June 9 from 11:00 a.m. – 1:00 p.m. ET Location: Exhibit and Poster Hall, Building B, Halls B2-B5 Poster number: 655 Session information: 236 - AAR09 - Pharmacological Studies of Antimicrobial Agents Pre-NDA (Phase 2/3): New Agents Between Phase 2 and FDA Approval

Additional activity:

Tetraphase will have a medical information booth set up throughout the ASM Microbe Conference. Booth number: 3221 Booth hours: Friday, June 8 from 10:30 a.m. – 5.00 p.m.; Saturday, June 9 from 10:30 a.m. – 5:00 p.m.; and Sunday, June 10 from 10:00 a.m. – 4:00 p.m.

Additional mentions:

Poster title:  A Multi-Site Study Comparing A Commercially Prepared Dried MIC Susceptibility System to the CLSI Broth Microdilution Method for Eravacycline Using Fastidious Organisms Date and time: Saturday, June 9 from 11:00 a.m. – 1:00 p.m. ET Location: Exhibit and Poster Hall, Building B, Halls B2-B5 Poster number:   209 Session information: 219 - CPHM02 - Antimicrobial Susceptibility Testing: Gram-Positive and Fastidious Bacteria

Poster title:  A Multi-Site Study Comparing A Commercially Prepared Dried MIC Susceptibility System to the CLSI/ISO Broth Microdilution Method for Eravacycline Using Gram-Positive and Gram-Negative Non-Fastidious Organisms Date and time: Friday, June 8 from 11:00 a.m. – 1:00 p.m. ET Location: Exhibit and Poster Hall, Building B, Halls B2-B5 Poster number:   242 Session information: 042 - CPHM02 - Antimicrobial Susceptibility Testing: Gram-Negative Bacteria

Poster title:  Development of Eravacycline MIC Assay for Gram-Negative Bacteria on Microscan Dried Gram-Negative MIC Panels Date and time: Friday, June 8 from 11:00 a.m. – 1:00 p.m. ET Location: Exhibit and Poster Hall, Building B, Halls B2-B5 Poster number:   235 Session information: 042 - CPHM02 - Antimicrobial Susceptibility Testing: Gram-Negative Bacteria

Full abstracts can be found on the ASM website at www.asm.org .

About Tetraphase Pharmaceuticals, Inc. Tetraphase is a biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention. The Company has created more than 3,000 novel tetracycline compounds using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which has completed phase 3 clinical trials and is under review for potential approval in complicated intra-abdominal infections by the FDA and the European Medicines Agency, and TP-271 and TP-6076, which are in phase 1 clinical trials. Eravacycline is an investigational product only and has not been approved for commercial use. Please visit www.tphase.com for more Company information.

Forward-Looking Statements Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "anticipates," "believes," "expects," "plans," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether the Company's regulatory submission will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if any clinical candidate, including eravacycline obtains approval, it will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of our quarterly report on Form 10-Q for the period  ended March 31, 2018, filed with the Securities and Exchange Commission on May 3, 2018. In addition, the forward-looking statements included in this press release represent our views as of May 21, 2018. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.

Media and Investor Contact: Jennifer Viera jviera@tphase.com   617-600-7040

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Happiest Minds Extends Absa Banking Platform Reach

Updated Category News Views 34

Mauritius just handed Happiest Minds a useful, if modest, banking-tech scorecard. On November 19, 2026, the company said its cloud-native Arttha platform had been deployed to support selected capabilities within Spark by Absa, a digital banking and lifestyle app from Absa Bank (Mauritius). This is not the sort of announcement that lets anybody pencil in a giant revenue...

Continue Reading
California Budget Warning Puts Reserves Back in Focus

Updated Category News Views 118

California’s rainy-day umbrella is getting another hard look, and it should. State Controller Malia M. Cohen is pointing to the Legislative Analyst’s Office fiscal outlook as a reminder that budget discipline and stronger reserves are not ornamental good-government phrases. They are the difference between absorbing a revenue wobble and reaching for ugly fixes after...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 0

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 34

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
Youdao Sets December AGM With No Vote on the Table

Updated Category News Views 74

A shareholder meeting without a vote is more temperature check than showdown, and that is exactly what Youdao has scheduled for December 17, 2026. The company will gather shareholders from 3:00 p.m. to 5:00 p.m. Beijing time at its Beijing office, but it has made one point painfully clear: no proposal will be submitted for shareholder approval. For holders of NYSE: DAO,...

Continue Reading
JOYY Q3 Growth Shows More Than Livestreaming Muscle

Updated Category News Views 39

Revenue finally has more than one pair of legs at JOYY, and that matters a whole lot more than a flashy quarterly headline. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% from the prior quarter. Those are not microscopic moves, and the composition is the part that deserves the hard stare. JOYY is still rooted in...

Continue Reading
A Hybrid Book Bets on Muscles, Myth, and Machines

Updated Category News Views 66

Few publishing pitches ask readers to carry a barbell into Tartarus, but A R Quigley is plainly not chasing the middle of the bookstore. Doctrina Machina Learning Machine, released by Palmetto Publishing in November 2026, welds together a strength-training guide and an underground military science-fiction war story. That is an odd little contraption, no use pretending...

Continue Reading
Innoviz's 1-for-20 Split Is a Listing Lifeline Test

Updated Category News Views 93

A twenty-share pile of INVZ is about to become one share, and nobody should confuse that paperwork with a turnaround. Innoviz plans to enact a 1-for-20 reverse split at 11:59 p.m. Eastern on Friday, December 4, with split-adjusted trading expected when Nasdaq opens on December 7. This is a blunt instrument aimed at one immediate problem: getting the quoted share price...

Continue Reading
SAGA's Radar Assays Tighten the Trapper North Case

Updated Category News Views 188

Rock that keeps showing up where the model says it should is the sort of boring news a junior miner desperately needs. SAGA Metals has put out fresh assay results from Radar’s Trapper North area, and the useful part is not merely a loud grade in one hole. It is the apparent persistence of thick titanium-vanadium-iron oxide mineralization across tighter-spaced drilling....

Continue Reading
Scenthound’s Franchise Award Spotlights a Real Test

Updated Category News Views 169

A clean dog may not sound like a growth story, yet Scenthound has turned that neglected chore into a surprisingly serious franchise proposition. The company has won the International Franchise Association’s Emerging Franchisor Award after building its dog-hygiene concept from a 2015 founding into a network with more than 180 open locations. That is a respectable piece...

Continue Reading

Top 5 Most Recently Viewed Articles

Melissa Tapanes Llahues Takes Charge as BASF President

Updated Category News Views 200

Melissa Tapanes Llahues Installed as President of BASF Bercow Radell Fernandez Larkin & Tapanes Partner continues her leadership across the development sectors Melissa Tapanes Llahues, an esteemed land use attorney and civic leader, has been officially installed as President of the Builders Association of South Florida (BASF), a key player in the region's development...

Continue Reading
Petco's Q2 2025 Results: A Look at Performance and Projections

Updated Category News Views 217

Petco's Q2 2025 Financial Results Overview Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) has revealed its financial performance for the second quarter of 2025, showcasing various achievement metrics and prospects for the remainder of the fiscal year. With a commitment to ongoing improvement, Petco has raised its earnings outlook and emphasized a strong economic...

Continue Reading
Empowering Women in STEM: A Transformative Networking Opportunity

Updated Category News Views 309

Empowering Women in STEM: A Transformative Networking Opportunity On November 12, a groundbreaking event titled "Connecting Our Talents; Women in STEM" will take place, bringing together female STEM students from various educational institutions. This event aims to highlight emerging talents and connect them with industry professionals, creating an invaluable network for...

Continue Reading
Analyzing Market Sentiment for Simpson Manufacturing Co Inc.

Updated Category News Views 260

Understanding Market Sentiment for Simpson Manufacturing Co Inc Simpson Manufacturing Co Inc's (NYSE: SSD) short interest has experienced a notable increase, with reports indicating a surge of 6.31% since the latest update. Currently, approximately 1.10 million shares have been sold short, which accounts for about 3.37% of the total shares available for trading. This...

Continue Reading
Growth of Hemp-Based Foods Market: Insights and Trends

Updated Category News Views 104

The Hemp-Based Foods Market: A Growing Trend The hemp-based foods market is experiencing remarkable growth, with projections indicating it will hit $10.6 billion by 2033. This marks a significant increase from $5.4 billion in 2023, boasting a compound annual growth rate (CAGR) of 7.2%. This upward trend shows a clear shift in consumer preferences toward plant-based diets,...

Continue Reading